Praxis Precision Medicines
Praxis Precision Medicines is a biotechnology company based in Boston, Massachusetts, specializing in developing precision therapies for central nervous system disorders using human genetics and translational tools.
Company Overview
Praxis Precision Medicines is a biotechnology firm focused on developing precision therapies for central nervous system disorders. The company employs patient-guided development strategies to identify therapeutic targets through human genetics and validate these targets and product candidates using translational tools. Praxis emphasizes efficient and rigorous clinical development paths to achieve proof-of-concept in humans. Headquartered at 99 High Street, 30th Floor, Boston, Massachusetts 02110, Praxis also maintains an Expanded Access Policy for investigational drugs under specified conditions.
Central Nervous System Disorders
Praxis Precision Medicines specializes in creating therapies aimed at central nervous system disorders. By focusing on therapeutic targets identified through human genetics, the company is able to develop more effective treatment options. The ultimate goal is to improve patient outcomes through precision medicine. Praxis utilizes comprehensive translational tools to confirm the potential of each target and product candidate, ensuring a strategic approach to developing treatments for these complex conditions.
Clinical Trials
Praxis conducts several clinical trials to advance its therapies for central nervous system disorders, including EMBOLD, EMBRAVE, and ESSENTIAL3. These trials are structured to provide robust evidence of the efficacy and safety of the company's product candidates. By focusing on efficient and rigorous clinical development, Praxis aims to achieve rapid proof-of-concept in human subjects, thereby accelerating the availability of new treatments for patients.
Expanded Access Policy
Praxis Precision Medicines offers an Expanded Access Policy to provide investigational drugs to patients outside of clinical trials under certain conditions. This policy underscores the company's commitment to meeting patient needs and improving access to potentially lifesaving treatments. The Expanded Access Policy is designed to ensure that patients who might benefit from these investigational therapies have an available pathway while adhering to regulatory guidelines and ethical standards.